WO2022006143A1 - Zinc oxide particles, photostable uv filters, and methods of use thereof - Google Patents

Zinc oxide particles, photostable uv filters, and methods of use thereof Download PDF

Info

Publication number
WO2022006143A1
WO2022006143A1 PCT/US2021/039667 US2021039667W WO2022006143A1 WO 2022006143 A1 WO2022006143 A1 WO 2022006143A1 US 2021039667 W US2021039667 W US 2021039667W WO 2022006143 A1 WO2022006143 A1 WO 2022006143A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
zinc oxide
dispersion
oxide particles
coated particles
Prior art date
Application number
PCT/US2021/039667
Other languages
English (en)
French (fr)
Inventor
Harry W. Sarkas
Christopher C. BOFFA
Original Assignee
Nanophase Technologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanophase Technologies Corporation filed Critical Nanophase Technologies Corporation
Priority to CN202180055274.9A priority Critical patent/CN116261553A/zh
Priority to AU2021299291A priority patent/AU2021299291A1/en
Priority to KR1020217042724A priority patent/KR102391600B1/ko
Priority to KR1020227013753A priority patent/KR20230020936A/ko
Priority to MX2023000248A priority patent/MX2023000248A/es
Priority to IL299410A priority patent/IL299410A/en
Priority to CA3184737A priority patent/CA3184737A1/en
Priority to JP2022581353A priority patent/JP2023532922A/ja
Publication of WO2022006143A1 publication Critical patent/WO2022006143A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G9/00—Compounds of zinc
    • C01G9/02—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B01J21/066—Zirconium or hafnium; Oxides or hydroxides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
    • B01J35/39—Photocatalytic properties
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G9/00—Compounds of zinc
    • C01G9/006—Compounds containing, besides zinc, two ore more other elements, with the exception of oxygen or hydrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/62—Coated
    • A61K2800/622—Coated by organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/62—Coated
    • A61K2800/63—More than one coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/65—Characterized by the composition of the particulate/core
    • A61K2800/651—The particulate/core comprising inorganic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/88—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by thermal analysis data, e.g. TGA, DTA, DSC
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/80—Particles consisting of a mixture of two or more inorganic phases
    • C01P2004/82—Particles consisting of a mixture of two or more inorganic phases two phases having the same anion, e.g. both oxidic phases
    • C01P2004/84—Particles consisting of a mixture of two or more inorganic phases two phases having the same anion, e.g. both oxidic phases one phase coated with the other
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/60—Optical properties, e.g. expressed in CIELAB-values

Definitions

  • Zinc oxide is a wide band-gap semiconductor with a reported band gap of 3.3-3.4 eV, making it an ideal candidate for a wide variety of applications including use as a primary white pigment [1 ,2], a variety of electronic, optoelectronic, and magnetooptic devices [3,4], and as a broad spectrum UV filter for topical sunscreen applications [5-7,43-45].
  • the use of zinc oxide in sunscreen has received particular attention recently as one of only two GRASE (Generally Regarded as Safe and Effective) sunscreen actives in the FDA proposed rule [45].
  • Pigmentary particles typically have larger sizes (from greater than 300 nm to about 16 pm) in order to scatter visible light, while particles used in UV filters typically have small particle sizes (300 nm or less) in order to avoid scattering light.
  • zinc oxide As a primary pigment, zinc oxide possesses the undesirable characteristic of developing a yellow coloration when subjected to mechanical grinding or high doses of UV radiation in vacuo. Any deviation from pure white is commercially unacceptable for use as a pigment, and traditionally was unacceptable when used as a UV filter or in cosmetic applications.
  • the origin of this trait was extensively studied using reflectance spectroscopy on large pigmentary sized particles by Cordaro,[1] who attributed the origin of the coloration to the formation of oxygen vacancies in zinc oxide and went on to extensively characterize the intrinsic defect levels in bulk single crystal zinc oxide [2].
  • the characterization of the intrinsic defect levels has continued and has been presented in summary [4].
  • the types of native defects in zinc oxide are presented in FIG. 1.
  • the native donor defects in zinc oxide are the electron donor defects Zn[ , Zn , Znf, V Q ,
  • Zinc oxide particles both absorb and scatter UV radiation, with the former playing a larger role as particle size decreases.
  • the absorption of UV radiation in inorganic UV filters including zinc oxide results in the formation of electron-hole pairs known as excitons.
  • Excitons are known to react with molecular oxygen through an electron transfer reaction to produce superoxide anion radicals.
  • Superoxide anion radical is a highly reactive and aggressive species responsible for the formation of a variety of reactive oxygen species, including hydroxyl radical (OH ⁇ ), lipid alkoxy radicals, lipid peroxyl radicals, singlet oxygen and nitric oxide. These species can initiate or participate in chain reactions and contribute to detrimental effects on skin health. Such reactions may be impeded by sequestering the charge carriers created from UV absorption through targeted surface treatments [30,31] or through quenching of the exciton species.
  • Defects may be introduced into zinc oxide to quench excitons.
  • One method of introduction of defects for quenching excitons is described in US Patent No. 6,869,596 to Knowland et al.
  • Luminescent traps or killer sites were introduced into zinc oxide particles smaller than 200 nm by thermal reduction using hydrogen to remove oxygen. The introduction of traps serves the purpose of trapping electrons and holes created upon excitation of the zinc oxide particles with UV radiation. The particles were believed to contain excess Zn 2+ ions within the absorbing core were demonstrated to impart some reduction in photocatalytic effect
  • the present invention is zinc oxide particles.
  • the particles have an 0:Zn ratio of at least 0.99, an average particle size of 10 to 300 nm, and a sufficient concentration of oxygen vacancies and zinc vacancies to give a dispersion of the particles in C12-C15 alkyl benzoate an orange to tan color corresponding to a DE value of at least 15 in a Dispersion Color Test.
  • the particles contain no aggregates and have no detectable particles 500 nm or larger, on a number-weighted basis.
  • the present invention is zinc oxide particles having average particle size of 10 to 300 nm.
  • the particles are stoichiometric zinc oxide, the particles have a DE value at most 10 in the DPPH Photocatalytic Stability Test, and the particles have a DE value at least 15 in the Dispersion Color Test.
  • the present invention is coated particles, comprising (a) zinc oxide particles, and a silica coating on the zinc oxide particles.
  • the zinc oxide has (i) an 0:Zn ratio of at least 0.99, and (ii) a sufficient concentration of oxygen vacancies and zinc vacancies to give a dispersion of the particles in C12-C15 alkyl benzoate an orange to tan color corresponding to a DE value of at least 15 in a Dispersion Color Test.
  • the coated particles have an average particle size of 10 to 300 nm.
  • the particles contain no aggregates and have no detectable particles 500 nm or larger, on a number-weighted basis.
  • the present invention is coated particles, comprising (a) zinc oxide particles, (b) an organic moiety-containing coating, on the zinc oxide particles.
  • the zinc oxide particles have (i) an 0:Zn ratio of at least 0.99, and (ii) a sufficient concentration of oxygen vacancies and zinc vacancies to give a dispersion of the particles in C12-C15 alkyl benzoate an orange to tan color corresponding to a DE value of at least 15 in a Dispersion Color Test.
  • the coated particles have an average particle size of 10 to 300 nm.
  • the particles contain no aggregates and have no detectable particles 500 nm or larger, on a number-weighted basis.
  • particle size means the average diameter of the image of the particle as viewed by electron microscopy.
  • particle size is used in this manner unless otherwise stated.
  • average particle size means the average of the particle sizes of a collection of particles or that calculated using a spherical model from the specific surface area of particles measured in m 2 /g determined using the Brunauer-Emmett-Teller (BET) method consistent with fully-dense particles.
  • BET Brunauer-Emmett-Teller
  • n 0:Zn
  • zinc oxide UV filter means zinc oxide having an average particle size of at most 300 nm.
  • photostable “photocatalytically stable” and “super-photostable” all refer to the reduction or elimination of the same property of zinc oxide, the chemical reactivity of excitons produced by light absorption.
  • the terms each refer to a different degree of reduction of reactivity, with “super-photostable” being the least reactive and “photostable” being the most reactive, with each having a separate test, one more sensitive than the next.
  • the test to determine if a zinc oxide powder is photostable is described in US Pat. No. 9139737, the test for photocatalytically stable is described below, and the test for super-photostable is described in US Patent Publication, Pub. No. 2018/0291210.
  • organic moiety-containing coating means a surface coating containing - CHs and/or -CH2- moieties. Examples include particles surface treated with silanizing agents, particles coated with propylsilsesquioxane/dimethiconol/silicate crosspolymer, particles surface treated with a plant-based phosphatide, and particles surface treated by esterifying fatty alcohols or polyglyceryl (polyol) compounds. These surface coatings and treatments may be used to make the particles hydrophobic.
  • FIG. 1 is a band diagram illustrating the energy levels of defects in ZnO.
  • FIG. 2 is a graph showing the thermogravimetric analysis (TGA) of the zinc oxide powders of Examples 1-4.
  • FIG. 3 is graph of the results of the DPPH Photocatalytic Stability Test (horizontal axis) versus the results of the Dispersion Color Test (vertical axis) for the zinc oxides powders of Examples 1-15.
  • compositions of Knowland et al. are formed by thermal reduction in hydrogen at elevated temperature resulting in the removal of oxygen, and therefore are non- stoichiometric with excess zinc.
  • Such zinc oxide compositions may be identified using thermogravimetric analysis, showing a weight gain in air starting above 400 °C caused by the re-oxidation of the particles. It has been reported [9] that particles of analogous overall composition (described as Zn/ZnO core shell particles) generate free radicals and other reactive oxygen species in the dark. It was confirmed through a free radical test carried out in the dark that the particles of Knowland et al. share this behavior of generating free radicals in a dark environment. The generation of free radicals makes these particles less desirable for use on skin.
  • the present invention makes use of zinc oxide particles which are stoichiometric, do not contain significant aluminum or transition metal dopants, have an average particle size of 10 to 300 nm, and which contain a sufficient concentration of defects to quench excitons making the particles photostable and photocatalytically stable.
  • the optional further addition of one or more coatings improves the photostability and photocatalytic stability, and allows for improved compatibility with cosmetic formulations.
  • concentration of defects results in a characteristic orange to tan color when dispersed in a liquid carrier, the color has recently become commercially acceptable for cosmetic formulations due to changes in consumer taste.
  • the photocatalytic stability and color result from a threshold concentration of defect states which are responsible both for the color through defect state absorption and for the low photocatalytic activity through exciton trapping.
  • the yellow aspect of such coloration has been attributed to oxygen vacancy defects.
  • the particles are stoichiometric ZnO, it may be surmised that the electron donating oxygen vacancy defects present in the particles do not result from the presence of excess zinc atoms, but rather from atomic disorder together with a balance of electron acceptor zinc vacancy defects.
  • the particles of the invention are also non-pigmentary in particle size (that is, an average particle size below 300 nm), and therefore do not substantially scatter visible light. This allows them to be used without imparting significant color when applied to the skin and actually somewhat improving the aesthetic character of formulas containing the particles relative to those containing conventional white zinc oxide.
  • the particles have an average particle size of at most 300 nm, including an average particle size of at most 100, 200, and 300 nm, more preferably an average particle size of 10 nm to 200 nm, most preferably an average particle size of 15 nm to 200 nm, such as 20, 30, 40, 50, 60, 70, 80, 90,100, 110, 120, 130, 140,
  • Pigmentary sized (an average particle size >300 nm for zinc oxide) UV absorbing particles are generally characterized by sufficiently low absorption coefficients in the wavelength region 290-400 nm that their practical use in UV protective compositions is excluded because they do not provide sufficient SPF at normal concentration levels. Furthermore, when the particle size is less than 10 nm, the particles are unable to efficiently quench excitons regardless of the concentration of vacancies, because the effective exciton radius in zinc oxide is large enough to extend out of the particles. Such small particles will not be photocatalytically stable.
  • Agglomerates are defined as collections of weakly bound particles bound by electrostatic interactions. Aggregates are defined as particles bound by strong interactions such as covalent or ionic bonding. The two can be distinguished using by dispersing the particles using low intensity mixing combined with ultrasonication followed by detection and particle size analysis using laser light scattering as described in ISO 13320:2009 (Particle size analysis — Laser diffraction methods). Agglomerates will be broken down revealing their constituent particles while aggregates will remain at the nominal aggregate size and be detected as such. Analyzers suitable for dispersing powders for measurement and determining particle size distributions by this method are the Horiba LA910, the Horiba 960, or equivalents.
  • the zinc oxide particles of the invention contain no aggregates and have no detectable particles 500 nm or larger, on a number- weighted basis.
  • the presence of such aggregates results in scattering of both visible and UV light, give the product both poor aesthetics and a reduced absorption of UV light.
  • the particles to be analyzed are dispersed in a fluid other than isopropanol, they must first be diluted with isopropanol. Dry powders must first be dispersed into isopropanol before analysis.
  • the particles are stoichiometric, that is the zinc oxide particles have a ratio of 0:Zn (referred to as “n”) of > 0.99. This is determined by any mass gain features showing a distinct inflection point with an onset above 400 °C during thermogravimetric analysis under an oxygen atmosphere, and may be calculated assuming all mass gain is oxygen.
  • n > 0.999, determined by the lack of any mass gain features greater than 0.02% showing a distinct inflection point with an onset above 400 °C during thermogravimetric analysis under an oxygen atmosphere. Thermogravimetric analysis of the particles of Knowland et al.
  • Particle stoichiometry is determined using thermogravimetric analysis performed under an atmosphere of pure oxygen in the range 25 °C to 800 °C at scan rates of 10 °C/minute to 20 “C/minute in a platinum pan.
  • a suitable instrument has a precision of 0.01 %.
  • Suitable instruments include TA Instruments Q Series 50 TGA Analyzer or equivalent instruments.
  • the baseline sample mass is taken as that at a temperature beyond that of mass loss due to gas desorption for dry, uncoated powders, or beyond that of ignition due to coating chemistry (in the case of dry, coated powders) or beyond that of ignition due to solvent and/or dispersant (in the case of coated powders or dispersions).
  • This baseline point is taken to be reflective of the base zinc oxide composition.
  • the combination of being stoichiometric, together with orange to tan color when dispersed in a liquid carrier of sufficient depth as described below, means that the ZnO particles comprise oxygen vacancy defects ( V Q and/or V 0 ) and the zinc vacancy defects (V Zn and/or V Zn ), in substantially the same number, to provide substantial exciton quenching, so that the particles are photocatalytically stable.
  • the stoichiometric zinc oxide is a non-pigmentary particle having low photocatalytic activity that is stoichiometric, in which the low photocatalytic activity is due to a sufficient concentration of charge-balanced intrinsic defects (that is, balanced oxygen vacancies and zinc vacancies) that can serve as exiton traps, and are in a sufficient concentration for identification by having a color past a threshold level of darkening.
  • charge-balanced intrinsic defects that is, balanced oxygen vacancies and zinc vacancies
  • the photocatalytic stability of zinc oxide (ZnO) is measured using the test described below. This test is referred to as the “DPPH Photocatalytic Stability Test.”
  • DPPH DPPH Photocatalytic Stability Test
  • 0.025 g ⁇ 0.001 g of ZnO powder on an actives basis is added to six 50 mL disposable plastic beakers.
  • 0.0125% DPPH di(phenyl)-(2,4,6-trinitrophenyl) iminoazanium, also referred to as diphenylpicrylhydrazyl; CAS Number 1898-66-4
  • BCS ethylene glycol butyl ether
  • 0.025 g ⁇ 0.001 of zinc oxide actives are added from dispersion of known zinc oxide content to six 50 mL disposable plastic beakers.
  • a nominal 0.0125% DPPH solution is prepared in BCS (ethylene glycol butyl ether) where the concentration of BCS is adjusted in a quantity sufficient manner to compensate for the liquid dispersion carrier and any other excipient ingredients in the zinc oxide containing dispersion. 19.975 g ⁇ 0.001 of the adjusted nominal 0.0125% DPPH in BCS solution is added to each beaker containing zinc oxide dispersion. Samples are mixed thoroughly with a glass stir rod, and each beaker is sonicated for 60 seconds, ensuring the particles are well- dispersed throughout the solution. After sonication, the sample is transferred to a labelled scintillation vial.
  • BCS ethylene glycol butyl ether
  • the pre-irradiated samples are measured on a Konica Minolta colorimeter CM-600D Colorimeter or suitable equivalent colorimeter calibrated using a NIST traceable white tile. After taking the measurements, the samples are irradiated. The test mixtures are exposed to UV light in a Q-Labs QUV weatherometer using UVB bulbs at 1.28 Wm- 2 s '1 at a constant temperature of 50 °C for exactly 5.5 minutes. Finally, the post-irradiated samples are measured on the colorimeter. Photocatalytic stability following UV exposure is indicated by the persistence of the purple color due to the absorption band of the dye at 520 nm. Photocatalytic stability may be expressed as the total color change relative to a standard (DE in L*a*b* color space) for a stated UV exposure time. DE is calculated from the following expression, as per the CIE76 definition:
  • L * 2 , a 2 , and b 2 are the color coordinates of test mixture post irradiation and where L ⁇ , a ⁇ , and b are the initial color coordinates of test mixture prior to irradiation. Data is reported as the average DE value of the six samples.
  • the color of zinc oxide (ZnO) is measured using the test described below.
  • the zinc oxide powder has a sufficient concentration of vacancy defect to have substantial exciton quenching (that is, the powder is photocatalytically stable) if it has a DE value of at least 15 in the following test. This test is referred to as the “Dispersion Color Test”.
  • a carrier solution of 4.30 ⁇ 0.1% Hostaphat KW 340D (INCI Name: Triceteareth-4 Phosphate) in Finsolv TN (INCI Name: C12-15 Alkyl Benzoate) is first prepared. For powder samples, 3.00 ⁇ 0.01 g of zinc oxide powder on an actives basis is added to a scintillation vial and diluted to a total of 10.00 ⁇ 0.01 g with carrier solution.
  • the Dispersion Color Test preferably the have a DE value of at least 16, 17, 19,
  • the particles do not contain chromium or manganese, which may be determined by elemental analysis.
  • the zinc oxide is not doped with silicon or aluminum, which may be confirmed by the color of the zinc not being pure white.
  • the stoichiometric zinc oxide particles may be prepared as a dry powder through a vapor phase formed by a plasma process using a very high cooling rate, in an environment containing sufficient oxygen to ensure a stoichiometric product.
  • the zinc oxide particles When present as a dry powder, the zinc oxide particles will appear white due to light scattering, even though the actual color of the particles will become apparent when wetted with a liquid carrier, in the form of a dispersion.
  • - IQ - zinc oxide particles and powder containing defects may be prepared by introducing defects into stoichiometric zinc oxide particle in a liquid carrier through mechanical stress.
  • Plasma-based particle production methods are well suited to produce the stoichiometric zinc oxide particles [10-16], particularly with the methods described in US Patent Nos. 5,460,701 and 5,874,684.
  • the method described therein will be referred to as “transferred arc physical vapor synthesis”.
  • zinc vapor is generated by a transferred arc in a geometry where the magnetic fields of the cathodic and anodic plasma jets produce a projected merged plasma jet of high velocity that contains saturated vapor of the product precursor. The velocity of this plasma jet leads to rapid cooling in a non-equilibrium process.
  • This vapor becomes supersaturated and forms into particles via a condensation nucleation process in which the condensing particles are exposed to oxygen-containing gas to complete the oxidation reaction.
  • the oxidant may further be used to concomitantly dilute the emerging zinc oxide particle stream via micro-mixing to control particle size.
  • This dilution process which generates a zinc oxide aerosol, may be used to quench the emerging particle stream and may be used to control annealing, oxidation, primary particle growth, and particle coalescence.
  • This zinc oxide aerosol is finally mixed with diluent/transport gas which transports the aerosol to a collector where the product is collected as an electrostatically bound powder consisting of weak agglomerates.
  • This structure is a relatively open one which can support a variety of intrinsic defect states [4]. Rapid cooling may be used to “freeze” varying levels of atomic disorder into the zincite crystal structure and control the concentration of defect states as particles are produced. Under certain combinations of process factors, powders are produced which display coloration which can be attributed to the presence of crystal defects. Under certain combinations of process conditions, this coloration may be associated with the presence of excess zinc atoms indicating incomplete oxidation, which is undesirable. Such undesirable materials are sub-stoichiometric zinc oxide which necessarily will display a mass gain showing a distinct inflection point with an onset above 400 °C when measured by thermogravimetric analysis under an oxygen atmosphere.
  • stoichiometric zinc oxide is formed which display deep orange to tan coloration when dispersed in nonaqueous liquids.
  • Example 1 below, provides one set of such conditions.
  • a desirable zinc oxide product simultaneously satisfies the criteria of (1) DE > 15 in the Dispersion Color Test, (2) DE ⁇ 10 in the DPPH Photocatalytic Stability Test, (3) an average particle size of 10-300 nm, and (4) are stoichiometric with respect to zinc and oxygen ratio.
  • the stoichiometric zinc oxide particles may also be prepared in a dispersion, preferably in a non-aqueous liquid medium, through the application of sufficient mechanical stress to induce balanced donor and acceptor defects in stoichiometric zinc oxide.
  • Stoichiometric composition in these cases are verified by the absence of mass gain related to oxidation as previously specified relative to the baseline mass established following the ignition of all liquid carriers and surface treatments.
  • Mechanical stress may be applied using a variety of methods, preferably with stirred media mills. The mechanical stress used to create atomic disorder resulting in a sufficient concentration of defects may be applied to any stoichiometric zinc oxide to enhance the concentration of radical trapping defects.
  • Stoichiometric zinc oxide generated in this manner also simultaneously satisfies the criteria of (1) DE > 15 in the Dispersion Color Test, (2) DE ⁇ 10 in the DPPH Photocatalytic Stability Test, (3) average particle size of 10-300 nm, and (4) are stoichiometric with respect to zinc and oxygen ratio. Even though the stoichiometric zinc oxide is prepared in a dispersion, the liquid medium may be removed by evaporation to obtain a dry powder.
  • the zinc oxide may be surface treated or coated using an inorganic oxide in order to further reduce photocatalytic activity of the particles.
  • Such surface coatings also prevents dissolution of zinc into the formulations (Zn(ll) ion leakage), which can cause emulsion destabilization or formation of precipitates.
  • Methods of applying surface treatments are well known.
  • Preferred oxides for surface treatment are silica [18-20] and alumina [19]. Such silica and alumina coatings do not affect the color in the Dispersion Color Test.
  • Inorganic surface treatments may be applied at 0.5%- 40% of the mass of the zinc oxide particle with the preferred range being 2.0%-20% of the mass of the particle and is adjusted based on the particle specific surface area with larger values of specific surface area typically requiring higher levels of surface treatment.
  • the stoichiometric zinc oxide is first surface treated using an inorganic oxide before a further surface treatment or coating described below.
  • the zinc oxide particles may be coated with one or more organic moiety-containing coatings in order to increase the hydrophobicity of the powders. Such coating and surface treatments typically do not affect the color in the Dispersion Color Test. Such coating and surface treatments may be applied uncoated particles or particles coated with an inorganic oxide.
  • the zinc oxide may be surface treated with a silanizing agent.
  • the silanizing agent may be applied to the surfaces of particles either in the raw state or after being first surface treated using an inorganic oxide.
  • the silanizing agent may be any substance that provides functionalized polysiloxanes on the surface of the particles.
  • silanizing agents are well known [21-32] and include reactive silicone and silane hydrophobizing surface treatments (for example, triethoxycaprylylsilane, octadecyltriethoxysilane, hydrogen dimethicones (CAS Numbers 68037-59-2 / 69013-23-6 / 70900-21-9) and CAS Number 69430-47-3 (Siloxanes and Silicones, di-Me, reaction products with Me hydrogen siloxanes and 1 ,1 ,3,3-tetramethyldisiloxane)).
  • the slianizing surface treatments serve to hydrophobized the particles in order to maintain them in the oil phase of UV protective topical preparations and impart water resistance.
  • the zinc oxide particles are coated using crosspolymers described in US Patent Publication, Pub. No. 2018/0291210, such as propylsilsesquioxane/dimethiconol/silicate crosspolymer which have been demonstrated to further suppress UV induced free radical generation of zinc oxide particles thereby allowing for enhancement of antioxidant activity and suppression of free radicals generated in the skin upon UV exposure, as compared to typical zinc oxide powders.
  • Zinc oxide particles having this coating are super-photostable.
  • US Patent Publication, Pub. No. 2018/0291210 describes a test for photostability and the criteria for determining if a zinc oxide powder super-photostable.
  • the zinc oxide may be surface treated with a plant-based phosphatide. Methods for this surface treatment have been taught in the art [33-35]. For example, a suitable phosphatide may be dissolved in a USP grade solvent such as USP heptane, sprayed onto the powder surface, dried, and subsequently heated at 100-150 °C to yield a permanently hydrophobic powder. The preferred range of phosphatide is 0.5- 25% by weight and a more preferred level of phosphatide is 1.0-10% by weight. The preferred phosphatide is lecithin. [44] The zinc oxide may be surface treated by esterifying fatty alcohols or polyglyceryl (polyol) compounds to the particle surface. Methods for this surface treatment have been taught [36].
  • a suitable fatty alcohol or polyglyceryl compound may be dissolved in a USP grade solvent such as USP isopropanol, sprayed onto the powder surface, dried, and subsequently heated at 130-200 °C to yield a permanently hydrophobic powder.
  • a USP grade solvent such as USP isopropanol
  • the preferred range of fatty alcohol or polyglyceryl compound is 0.5-25% by weight and a more preferred level of fatty alcohol or polyglyceryl compound is 1.0-10% by weight.
  • Suitable examples of fatty alcohols are stearyl alcohol, behenyl alcohol, octyldodecanol, and cetearyl alcohol.
  • polyglyceryl (polyol) compounds are polyglyceryl esters (for example, polyglyceryl-3 ricinoleate, polyglyceryl-6 ricinoleate, polyglyceryl-10 pentastearate and polyglyceryl-4 oleate), polyglyceryl polyesters (for example, polyglyceryl-4 diisostearate/polyhydroxystearate/sebacate, polyglyceryl-2 dipolyhydroxystearate and polyglyceryl-3 stearate/isostearate/dimer dilinoleate crosspolymer).
  • polyglyceryl esters for example, polyglyceryl-3 ricinoleate, polyglyceryl-6 ricinoleate, polyglyceryl-10 pentastearate and polyglyceryl-4 oleate
  • polyglyceryl polyesters for example, polyglyceryl-4 diisostearate/polyhydroxystearate/sebacate, polyglyceryl
  • the powder is hydrophobic. Hydrophobicity is measured using the following hydrophobicity test (this test is a visible water floatation test commonly used in the cosmetics industry, and is described in U.S. Patent No. 4,454,288). Approximately 30 ml. of deionized water is placed into a glass jar. Approximately 3.0 g ⁇ 0.30 g of the powder to be tested is added into the glass jar. The glass jar is tightly sealed, and the sample is swirled around 4 to 5 times and vigorously shaken 4 to 5 times, so that intimate contact between the water and the powder is achieved. The powder is considered to be hydrophobic if the powder is buoyant (floating on the surface of the water) and water is clear after 15 minutes. The sample is marginally hydrophobic if the powder is not buoyant but the water is clear after 15 minutes, or if the powder is buoyant but the water is not clear after 15 minutes.
  • a dispersion of the zinc oxide powder in a liquid carrier may be prepared, either from the as prepared stoichiometric zinc oxide particle or following one or more surface treatments.
  • the dispersion may be prepared by conventional formulation techniques. For example, the zinc oxide particles, an optional surfactant/dispersant and the liquid carrier may be combined in a vessel and stirred until homogenous. The dispersion may then be transferred to a mill, such as a media mill, and comminuted to achieve a desired average particle size.
  • the liquid carrier may be any fluid or wax that is lipophilic, preferably a cosmetically- acceptable fluid or wax, including mixtures thereof.
  • suitable liquid carriers include triglycerides (for example, caprylic/capric triglycerides), esters (for example, C12-C15 alkyl benzoate, isopentyl laurate, isopropyl isostearate, coco- ca pry late, coco-caprylate caprate, ethylhexyl isononanoate, tridecyl salicylate, ethylhexyl isononanoate, isodecyl salicylate, octyldodecyl neopentanoate, butyloctyl salicylate, jojoba esters and shea butter ethyl esters), natural oils and butters (for example, Simmondsia chinensis (jojoba) seed oil, shea butter, Argania spinosa (
  • the surfactant/dispersant may be any surfactant or dispersant that has strong acid- base interactions with the raw or surface treated zinc oxide particles.
  • suitable surfactants/dispersants include fatty alcohols and polyols (for example, stearyl alcohol, behenyl alcohol and cetearyl alcohol), fatty acids (for example, stearic acid and oleic acid), amino acids (for example, lauroyl lysine and myristoyl glutamate), polyglyceryl esters (for example, polyglyceryl-3 ricinoleate, polyglyceryl-6 ricinoleate, polyglyceryl-10 pentastearate and polyglyceryl-4 oleate), polyglyceryl polyesters (for example, polyglyceryl-4 diisostearate/polyhydroxystearate/sebacate, polyglyceryl-2 dipolyhydroxystearate and polyglyceryl-3 stearate/isostearate/dimer dilino
  • the zinc oxide particles may be present in the dispersion in an amount of 0.1-85.0% by weight, including 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 2.0%, 3.0%, 4.0%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, 10.0%, 15.0%, 20.0%, 25.0%, 30.0%, 35.0%, 40.0%, 45.0%, 50.0%, 55.0%, 60.0%, 65.0%, 70.0%, 75%, 80%, and 85% by weight.
  • the surfactant/dispersant may be present in the dispersion in an amount of 1.0- 100.0% of the mass of the zinc oxide particles, including 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 15.0%, 20.0%, 25.0%, 30.0%, 35.0%, 40.0%, 45.0%, 50.0%, 55.0%, 60.0%, 65.0%, 70.0%, 75.0%, 80.0%, 85.0%, 90.0% and 95.0%.
  • the surfactant is present in an amount of 2.0- 60.0% of the mass of the zinc oxide particles.
  • the amount of liquid carrier in the dispersion will be dependent on the amount of the zinc oxide particles and the amount of the surfactant present in the dispersion.
  • the carrier vehicle may be added in any suitable amount necessary to produce a desired dispersion.
  • the zinc oxide particles may be formed into the oil phase of a preparation or a powder preparation.
  • the preparation is suitable for topical application.
  • suitable preparations include emulsions (oil-in-water and water-in-oil emulsions), sprays, balms, sticks, powders, powder-to-cream preparations, lipophilic preparations and anhydrous preparations.
  • Preparations containing the zinc oxide particles may be formulated for use in a variety of different applications.
  • suitable formulations include cosmetics (for example, blushes, face powders, foundations, lipsticks, makeup bases and rouges), skin care products (for example, skin cleansing creams, lotions, liquids and pads; face and neck creams, lotions, powders and sprays; body and hand creams, lotions, powders and sprays; foot powders and sprays; moisturizers; night creams, lotions, powders and sprays; paste masks/mud packs; and skin fresheners) and sunscreens.
  • cosmetics for example, blushes, face powders, foundations, lipsticks, makeup bases and rouges
  • skin care products for example, skin cleansing creams, lotions, liquids and pads; face and neck creams, lotions, powders and sprays; body and hand creams, lotions, powders and sprays; foot powders and sprays; moisturizers; night creams, lotions, powders and sprays; paste masks/mud packs; and skin fresheners
  • sunscreens are particularly preferred formulations.
  • the formulations may be provided in any form suitable for topical administration, such as in the form of a topical suspension, lotion, cream, ointment, gel, hydrogel, foam, paste, tincture, liniment, sprayable liquid, aerosol, stick or powder.
  • the formulations may optionally include inactive ingredients, auxiliaries and/or additives such as co-emulsifiers, fats, waxes, stabilizers, thickeners, biogenic active ingredients, film formers, fragrances, dyes, pearlizing agents, preservatives, pigments, electrolytes and pH regulators.
  • a sunscreen may include the zinc oxide particles and an additional UV radiation protectant.
  • the UV radiation protectant may be any substance that absorbs, reflects and/or scatters UV radiation.
  • the sunscreen may optionally include sun protection factor (SPF) boosters or stabilizers such as methoxycrylene and polyester-8.
  • SPF sun protection factor
  • Suitable additional UV radiation protectants include titanium dioxide (T1O2), p-aminobenzoic acid (PABA), padimate O (OD-PABA, octyldimethyl-PABA, s-RABA), phenylbenzimidazole sulfonic acid (ensulizole, EUSOLEX® 232, PBSA, PARSOL® HS), cinoxate (2-ethoxyethyl p-methoxycinnamate), dioxybenzone (benzophenone-8), oxybenzone (benzophenone-3, EUSOLEX® 4360, ESCALOL® 567), homosalate (homomethyl salicylate, HMS), menthyl anthranilate (meradimate), octocry!ene (EUSOLEX® OCR, 2-cyano-3, 3-diphenyl acrylic acid, 2-ethylhexyIester), octyl methoxycinnamate (octinoxate
  • the additional UV radiation protectant has been approved by at least one of the regulatory agencies of the United States (U.S. Food and Drug Administration or FDA), Canada, the European Union, Australia, Japan, Korea, China, Mercosur, the Association of Southeast Asian Nations (ASEAN), the Commonwealth of Independent States (CIS) and the Gulf Cooperation Council (GCC).
  • U.S. Food and Drug Administration or FDA United States
  • ASEAN Association of Southeast Asian Nations
  • CIS Commonwealth of Independent States
  • GCC Gulf Cooperation Council
  • a zinc oxide suitable for use in sunscreen applications must also meet the criterion of having a Critical Wavelength (see 76 FR 35660, June 17, 2011, as amended at 76 FR 38975, July 5, 2011) of at least 370 nm when in the fully dispersed state such as that described in the Color Test. If this criterion is not satisfied, products formulated from the zinc oxide will not meet the standard of providing broad spectrum protection in selected jurisdictions (see US 21CFR201.327 and Health Canada Sunburn Protectants Monograph of October 12, 2006).
  • the Critical Wavelength is identified as the wavelength at which the integral of the spectral absorbance curve reaches 90 percent of the integral over the UV spectrum from 290 nm to 400 nm. The equation below defines the Critical Wavelength:
  • l 0 critical wavelength
  • A(l) mean absorbance at each wavelength
  • cM wavelength interval between measurements
  • a mean Critical Wavelength of 370 nm or greater is classified as broad spectrum protection.
  • All the zinc oxides of noncomparative examples, below, have Critical Wavelength values ranging from 376 nm to 380 nm.
  • the stoichiometric zinc oxide has a Critical Wavelength value of at least 370 nm, more preferably at least 375 nm, including 376 to 380 nm.
  • the coated particles, the multilayer coated particles, dispersions, or cosmetic/dermatological compositions have a Critical Wavelength value of at least 370 nm, more preferably at least 375 nm, including 376 to 380 nm.
  • Formulations that include the zinc oxide particles provide a variety of health benefits due to the low propensity of generating photo-radicals upon UV exposure as evidenced by performance in the DPPH Photocatalytic Stability Test.
  • One preferred aspect of the present invention includes the addition of antioxidants to dispersions containing the coated powders.
  • Antioxidants are oxidized when exposed to UV radiation, leading to a decrease in the antioxidative power.
  • zinc oxide and other metal oxides are photo-reactive, and produce free radicals upon UV radiation exposure.
  • Metal oxides, in combination with antioxidants would have a greater loss of AP than the antioxidants alone.
  • the relative AP value of the dispersion remains higher than that of the antioxidants alone. Because the coated powders are superphotostable, compositions of coated powders and antioxidants exhibit a synergistic effect together.
  • Dispersions may contain one or more antioxidant.
  • Antioxidants may include vitamins, antioxidant minerals, antioxidant proteins, antioxidant enzymes and coenzymes, phytonutrients, antioxidant hormones, mycosporine-like amino acids (MAAs), antioxidants derived from marine algae, and other types of antioxidants.
  • Antioxidants may be water soluble, fat soluble, or fat and water soluble. Suitable vitamins include vitamin A (including retinoids and carotenoids), vitamin C (ascorbic acid), vitamin E (tocopherols), and vitamin K.
  • Suitable retinoids include retinol, retinoic acid (tretinoin), retinal and retinyl palmitate.
  • Suitable minerals include copper, manganese, iodide and zinc.
  • Suitable enzymes and coenzymes include melatonin, superoxide dismutase, catalase, and glutathione peroxidase.
  • Suitable phytonutrients include carotenoids, flavonoids, phenolic acids, and nonflavonoid phenolics.
  • Suitable carotenoids include alpha-carotene, retinol, astaxanthin, beta- carotene, canthaxanthin, lutein, lycopene, and zeaxanthin.
  • Suitable flavonoids include hindered phenols, apigenin, luteolin, tangeritin, isohamnetin, kaempferol, myricetin, proanthocyanidins, quercetin, eriodictyol, hesperetin, naringenin, catechin, gallocatechin, epicatechin, epigallocatechin, thearubigins, daidzein, genistein, glycitein, resveratrol, pterostilbene, cyanidin, delphinidin, malvidin, pelargonidin, and petunidin.
  • Suitable phenolic acids include phenol, polyphenols, alkylated phenols, and hindered phenols.
  • Suitable phenols include butylated hydroxyanisole, butylated hydroxytluene, cannabinoids, capsaicin, carvacrol, cresol, estradiol, eugenol, gallic acid, guaiacol, thymol, tyrosine, and sesamol.
  • Gallic acid includes salts and esters of gallic acid, also known as gallates.
  • Suitable nonflavonoid phenolics include curcumin, flavonolignans, xanthones, and eugenol.
  • Suitable mycosporine-like amino acids include mono-substituted MAAs, such as mycosporine-gycine and mycosporine-taurine, di-substituted MAAs, such as palythenic acid and shinorine, and derivatized MAAs, such as palythine-threonine sulfate and palythine-threonine glycoside. Examples of suitable MAAs can be found in Wada et al. (2015).
  • Antioxidants derived from marine algae include ascorbate, glutathione, phlorotannins, eckol, eckstolonol, prenyl toluquinones, tetraprenyltoluquinols, sargothunbergol A, fucodiphlorethol, terpenoids, phycocyanin, phycocyanobilin, fucoxanthin, phlorotannin, and lutein.
  • antioxidants include bilirubin, citric acid, oxalic acid, phytic acid, n-acetylcysteine, uric acid, green tea, hydoxy-tryrosol, dihydo-quercetin, ubiquinone, glutathione, alpha-lipoic acid, folic acid, ellagic acid, caffeic acid, and phytoestrogens.
  • the antioxidants above also include any salt, ester or acid form of the antioxidant.
  • Dispersions may contain one or more phyto-extracts.
  • a “phyto-extract” is a substance obtained from a plant. Preferably, the phyto-extract imparts a color. Phyto-extracts must be compatible with non-aqueous compositions; stable in air; non-staining to skin; non-irritating to skin in the amount used; and non-toxic in the amounts used.
  • the phyto-extract has a purity level of at least 95%.
  • suitable phyto-extracts include curcumin, lycopene, beta-carotene, lutein, zeaxanthin, meso-zeaxanthin and anthocyanins. Sources of curcumin include turmeric.
  • Sources of lycopene include beets, cherries, goji berries, pink grapefruit, pomegranate, raspberries, red cabbage, red onions, strawberries, tomatoes and watermelon.
  • Sources of beta-carotene include apricots, cantaloupes, carrots, oranges, papayas, peaches, persimmons, pumpkins, summer squash, sweet potatoes, winter squash and yams.
  • Sources of lutein, zeaxanthin, and meso- zeaxanthin include avocados, broccoli, Brussels sprouts, cabbage, green beans, leafy greens, orange peppers, peas, spinach, yellow corn and zucchini.
  • Sources of anthocyanins include beets, black currants, blueberries, cherries, eggplant, figs, grapes, plums, prunes, red cabbage and red currants.
  • Phyto-extracts may be chemically modified by hydrolysis, hydrogenation, esterification or saponification. Phyto-extracts which normally impart a color may no longer impart a color if they have been chemically modified. For example, curcumin imparts a yellow color but tetra-hydro curcumin, which has been hydrogenated, is colorless.
  • Dispersions may contain one or more plant bio-extracts.
  • a “plant bio-extract” is a natural extract of a plant that provides a fragrance and may also provide a color. Plant bio-extracts must be compatible with non-aqueous compositions; stable in air; non-staining to skin; non-irritating to skin in the amounts used; and non-toxic in the amounts used.
  • plant bio-extracts Synthetic versions of plant bio-extracts are outside the scope of the term “plant bio-extract.”
  • suitable plant bio-extracts include arnica extract ( Arnica montana), basil extract ( Ocimum basilicum), boswellia extract (Boswellia sacra), calendula extract ( Calendula officinalis), chamomile extract (Anthemis nobilis), cinnamon oil ( Cinnamomum verum), clove oil ( Syzygium aromaticum), coptis extract ( Coptis aspleniifolia), echinacea extract ( Echinacea purpurea), eucalyptus oil ( Eucalyptus occidentalis), ginger root extract ( Zingiber officinale), grape seed extract ⁇ Vitis vinefera), green tea extract (Camilla sinensis), guggul resin extract ( Commiphora wightii), horse chestnut seed extract ( Aesculus hippocastanum), Japanese knot
  • the composition optionally includes a phyto-extract.
  • the phyto-extract may be selected to provide a color.
  • Phyto-extracts that do not impart a color may also be included in the composition.
  • Phyto-extracts must be compatible with non-aqueous compositions; stable in air; non-staining to skin; non-irritating to skin in the amounts used; and non-toxic in the amounts used.
  • the phyto-extract has a purity level of at least 95%. Examples of suitable phyto-extracts include curcumin, lycopene, beta- carotene, lutein, zeaxanthin, meso-zeaxanthin and anthocyanins. Sources of curcumin include turmeric.
  • Sources of lycopene include beets, cherries, goji berries, pink grapefruit, pomegranate, raspberries, red cabbage, red onions, strawberries, tomatoes and watermelon.
  • Sources of beta-carotene include apricots, cantaloupes, carrots, oranges, papayas, peaches, persimmons, pumpkins, summer squash, sweet potatoes, winter squash and yams.
  • Sources of lutein, zeaxanthin, and meso- zeaxanthin include avocados, broccoli, Brussels sprouts, cabbage, green beans, leafy greens, orange peppers, peas, spinach, yellow corn and zucchini.
  • Sources of anthocyanins include beets, black currants, blueberries, cherries, eggplant, figs, grapes, plums, prunes, red cabbage and red currants.
  • Phyto-extracts may be chemically modified by hydrolysis, hydrogenation, esterification or saponification.
  • Phyto-extracts which normally impart a color, such as curcumin may no longer impart a color if they have been chemically modified, such as tetra-hydro curcumin.
  • the composition may contain 0.01% to 5.0% phyto-extract, preferably 0.01% to 1.0% phyto-extract, including 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19% and 0.20% phyto-extract.
  • the composition optionally includes a plant bio-extract.
  • the plant bio-extract provides a fragrance and may also provide a color.
  • Plant bio-extracts must be compatible with non-aqueous compositions, such as being lipophilic or hydrophobic; stable in air; non-staining to skin; non-irritating to skin in the amounts used; and nontoxic in the amounts used.
  • suitable plant bio-extracts include arnica extract ( Arnica montana), basil extract ( Ocimum basilicum), boswellia extract (Boswellia sacra), calendula extract ( Calendula officinalis), chamomile extract (Anthemis nobilis), cinnamon oil ( Cinnamomum verum), clove oil ( Syzygium aromaticum), coptis extract ( Coptis aspleniifolia), echinacea extract ( Echinacea purpurea), eucalyptus oil ( Eucalyptus occidenta!is), ginger root extract ( Zingiber officinale), grape seed extract (Vitis vinefera), green tea extract ( Camilia sinensis), guggul resin extract ( Commiphora wightii), horse chestnut seed extract ( Aesculus hippocastanum), Japanese knotweed extract ( Polygonum cuspidatum), licorice extract ( Glycyrrhiza glabra), ne
  • the dispersion may optionally include extracts from algae species. These species include Hijikia fusiformis, Spirulina platensis, Aphanizomenon, Spirulina maxima, Sargassum kjellamanianum, S. siliquastrum, Rhodomela confervoides, Symphjocladia latiuscula, Kappaphycus alvarezzi, Botryococcus braunii, Dunaliella salina, Cystoseira crinite, Ecklonia stolonifera, Sargassum thunbergii, S. thunbergii, and Ecklonia cava.
  • algae species include Hijikia fusiformis, Spirulina platensis, Aphanizomenon, Spirulina maxima, Sargassum kjellamanianum, S. siliquastrum, Rhodomela confervoides, Symphjocladia latiuscula, Kappaphycus alvar
  • the composition may contain 0.10% to 10.0% plant bio-extract, preferably 2.0% to 6.0% plant bio-extract, including 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9% and 4.0% plant bioextract.
  • the composition optionally includes an oil-soluble antioxidant.
  • an antioxidant is present, the antioxidant is different than the phyto-extract.
  • suitable antioxidants include carotene, catechin, lycopene, resveratrol, Vitamin E or Vitamin A.
  • “Vitamin E” may refer to any of the tocopherol or tocotrienol compounds that constitute the Vitamin E family of compounds, such as alpha-tocopherol and gamma- tocotrienol.
  • the composition may contain 0.01% to 5.0% antioxidant, preferably 0.1% to 3.0% antioxidant, including 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% and 2.0% antioxidant.
  • the dispersion may contain one or more protist extract.
  • a “protist extract” is a substance obtained from a protist. Protists include eukaryotic organisms that are not animals, plants or fungi. Preferably the protist extract is a substance that is high in astaxanthins. Examples of suitable protist extracts include plankton extract and algae extract, particularly red algae extract.
  • the dispersion may optionally include a protist extract.
  • the protist extract is a substance that is high in astaxanthins.
  • suitable protist extracts include plankton extract and algae extract, particularly red algae extract.
  • the dispersion may contain 0.01% to 5.0% protist extract, preferably 0.1% to 3.0% protist extract, including 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% and 2.0% protist extract.
  • Cosmetic and dermatological preparations may include cosmetic ingredients, auxiliaries and/or additives, for example, co-emulsifiers, fats and waxes, stabilizers, thickeners, biogenic active ingredients, film formers, fragrances, dyes, pearlizing agents, preservatives, pigments, electrolytes, and pH regulators.
  • Suitable co- emulsifiers are, preferably, known W/O and also O/W emulsifiers, for example, polyglycerol esters, sorbitan esters or partially esterified glycerides.
  • Typical examples of fats are glycerides; waxes such as beeswax, paraffin wax or microcrystalline waxes, optionally in combination with hydrophilic waxes.
  • Stabilizers including metal salts of fatty acids, for example, magnesium, aluminum and/or zinc stearate.
  • thickeners include crosslinked polyacrylic acids and derivatives thereof, polysaccharides, such as xanthan gum, guar gum, agar, alginates and tyloses, carboxymethylcellulose and hydroxyethylcellulose, and fatty alcohols, monoglycerides and fatty acids, polyacrylates, polyvinyl alcohol and polyvinylpyrrolidone.
  • Biogenic active ingredients include plant extracts, protein hydrolyzates and vitamin complexes.
  • Customary film formers include, for example, hydrocolloids, such as chitosan, microcrystalline chitosan or quaternary chitosan, polyvinylpyrrolidone, vinylpyrrolidone/vinyl acetate copolymers, polymers of the acrylic acid series, and quaternary cellulose derivatives.
  • preservatives include parabens, diazolidinyl urea, iodopropynyl butylcarbamate, and sorbic acid.
  • pearlizing agents include glycol distearic esters, such as ethylene glycol distearate, fatty acids and fatty acid monoglycol esters. Dyes which may be used are the substances suitable and approved for cosmetic purposes.
  • Antioxidants such as amino acids, retinol, flavonoids, polyphenols, vitamin C and tocopherols, may also be included.
  • the cosmetic and dermatological preparations may be in the form of a solution, dispersion or emulsions; for example, sunscreen preparations may be in liquid, paste or solid form, for example as water-in-oil creams, oil-in-water creams and lotions, aerosol foam creams, gels, oils, marking pencils, powders, sprays or alcohol- aqueous lotions.
  • Solvents for these compositions include water; oils, such as triglycerides of capric acid or of caprylic acid, as well as castor oil; fats, waxes and other natural and synthetic fatty substances, esters of fatty acids with alcohols of low carbon number, for example with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids of low carbon number or with fatty acids; alcohols, diols or polyols of low carbon number, and ethers thereof, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether.
  • oils such as triglycerides of capric acid or of caprylic acid, as well as castor oil
  • the cosmetic and dermatological preparations may be in the form of solid sticks, and may include natural or synthetic waxes, fatty alcohols or fatty acid esters, liquid oils for example paraffin oils, castor oil, isopropyl myristate, semisolid constituents for example petroleum jelly, lanolin, solid constituents such as beeswax, ceresine and microcrystalline waxes and ozocerite, and high-melting waxes including carnauba wax and candelilla wax.
  • natural or synthetic waxes for example paraffin oils, castor oil, isopropyl myristate
  • semisolid constituents for example petroleum jelly, lanolin
  • solid constituents such as beeswax, ceresine and microcrystalline waxes and ozocerite
  • high-melting waxes including carnauba wax and candelilla wax.
  • Cosmetic preparations may be in the form of gels and preferably include water, organic thickeners, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxpropylmethylcellulose and inorganic thickeners, such as aluminum silicates, for example, bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • organic thickeners for example gum arabic, xanthan gum, sodium alginate
  • cellulose derivatives such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxpropylmethylcellulose
  • inorganic thickeners such as aluminum silicates, for example, bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • the zinc oxide and compositions containing the zinc oxide may be used in a method of protecting skin from light, including coating skin with a composition containing the zinc oxide particles.
  • the zinc oxide and compositions containing the zinc oxide may be used in a method of protecting keratinous material including coating the keratinous material with a composition containing the zinc oxide particles.
  • the zinc oxide and compositions containing the zinc oxide may be used in a method of protecting skin from light, including coating skin with a composition containing the zinc oxide particles.
  • the zinc oxide and compositions containing the zinc oxide may be used in a method of suppressing lipid peroxidation including coating skin with a composition containing the zinc oxide particles.
  • the zinc oxide and compositions containing the zinc oxide may be used in a method of preventing or reducing lines and wrinkles on the skin including coating skin with a composition containing the zinc oxide particles.
  • the zinc oxide and compositions containing the zinc oxide may be used in a method of preventing loss of elasticity of the skin including coating skin with a composition containing the zinc oxide particles.
  • the zinc oxide and compositions containing the zinc oxide may be used in a method of preventing thinning of the skin including coating skin with a composition containing the zinc oxide particles.
  • the zinc oxide and compositions containing the zinc oxide may be used in a method of protecting skin from environmental pollution including coating skin with a composition containing the zinc oxide particles.
  • USP grade zinc oxide particles having a hexagonal zincite crystal structure were produced via transferred arc physical vapor synthesis at a specific power input of 4.0 kW/kg ZnO and quench gas input of 5.3 ft 3 air/kg Zn vapor where the quench air is introduced at the closest point to the origin projected merged plasma jet that maintains a stable arc and utilizing an average transport air flow of 1300 ft 3 air/kg ZnO.
  • the resulting powder product has an average particle size of 40 nm, a DE value of 17.69 ⁇ 0.26 (95% Cl) in the Dispersion Color Test, a DE value of 7.22 ⁇ 0.29 in the DPPH Photocatalytic Stability Test, and DE value of 0.17 ⁇ 0.15 (95% Cl) in the DPPH Dark Radical Test.
  • Thermogravimetric analysis results, shown in FIG. 2 indicate the product to be stoichiometric ZnO.
  • USP grade zinc oxide particles having a hexagonal zincite crystal structure were produced via transferred arc physical vapor synthesis at a specific power input of 3.4 kW/kg ZnO and no quench gas input utilizing an average transport air flow of 1 ,130 ft 3 air/kg ZnO.
  • the resulting white powder product has an average particle size of 150 nm, a DE value of 9.51 ⁇ 0.10 (95% Cl) in the Dispersion Color Test and a DE value of 18.57 ⁇ 0.17 in the DPPH Photocatalytic Stability Test.
  • Thermogravimetric analysis results, shown in FIG. 2, indicate the product to be stoichiometric ZnO.
  • Example 2 The powder of Example 2 was calcined in air at 800 °C for 1 hour.
  • the resulting white powder product has an average particle size of 300 nm, a DE value of 9.69 in the Dispersion Color Test and a DE value of 34.80 in the DPPH Photocatalytic Stability Test.
  • Thermogravimetric analysis results, shown in FIG. 2, confirm the product to be stoichiometric ZnO.
  • Example 3 The powder of Example 3 was reduced in a hydrogen/nitrogen atmosphere.
  • the resulting powder product displayed a green luminescence when irradiated with UVA radiation, has a DE value of 16.50 in the Dispersion Color Test and a DE value of 16.45 in the DPPH Photocatalytic Stability Test.
  • the results of the DPPH Photocatalytic Stability Test are consistent with that of comparative compositions since the DE value is less than that of the parent zinc oxide and is statistically significant.
  • the results also clearly indicate that the material is not photocatalytically stable when compared to the stoichiometric zinc oxide and are, in fact, found to be less photocatalytically stable than some commercial zinc oxides that do not display noticeable coloration (see Example 15).
  • composition of this example also produced a DE value of 10.21 in the DPPH Dark Radical Test (see below), indicating that the composition produces free radicals in the dark, suggesting that this material is not ideal for topical UV protective formula environments. This is in sharp contrast to the stoichiometric zinc oxide.
  • Thermogravimetric analysis results shown in FIG. 2, indicate the product to be sub-stoichiometric ZnO based on the distinct mass gain feature with an onset at about 450 C°.
  • the TGA analysis may be used to calculate the composition which is approximately ZnOo.96 and is thus significantly deficient in oxygen, in sharp contrast with the stoichiometric zinc oxide.
  • Free radical generation of a zinc oxide powder in the absence of exposure to radiation is measured using the test described below. This test is referred to as the “DPPH Dark Radical Test.”
  • DPPH Dark Radical Test 0.025 g ⁇ 0.001 g of ZnO powder on an actives basis is added to six 50 mL disposable plastic beakers.
  • 0.0125% DPPH di(phenyl)- (2,4,6-trinitrophenyl) iminoazanium, also referred to as diphenylpicrylhydrazyl; CAS Number 1898-66-4
  • BCS ethylene glycol butyl ether
  • each sample is transferred to centrifuge tubes and centrifuged at 5000 RCF for 15 minutes followed by filtration using a 0.2 micron PVDF syringe filter to remove all particulate material.
  • 10 ml of this filtered solution is transferred into a new scintillation vial for color testing.
  • a Color Reference is prepared adding 19.950 g ⁇ 0.001 of 0.0125% DPPH in BCS solution and 0.025 g ⁇ 0.001 g of deionized water to a scintillation vial followed by thorough mixing. 10 ml of this reference solution is transferred into a new scintillation vial which serves as a Color Reference for color testing.
  • L 2 , a 2 * , and b 2 are the color coordinates of test samples and where L , a , and b are the color coordinates of Color Reference. Data is reported as the average DE value of the six samples.
  • a particle with no propensity for free radical generation in the dark should yield a solution which has no perceptible color difference from that of the Color Reference. Quantitatively, a particle is considered to generate free radicals in the absence of irradiation if DE>1.0 in the above DPPH dark radical test.
  • Example 1 The powder of Example 1 was surface treated with 2% lecithin on powder mass and dispersed in caprylic/capric triglyceride carrier at 72 weight % zinc oxide using 8% polyglyceryl-2 dipolyhydroxystearate on powder mass as a dispersant.
  • the powder of Example 1 was surface treated with 2% lecithin on powder mass and dispersed in caprylic/capric triglyceride carrier at 72 weight % zinc oxide using 8% polyglyceryl-2 dipolyhydroxystearate on powder mass as a dispersant.
  • the resulting dispersion product has a DE value of 17.98 in the Dispersion Color Test and a DE value of 7.12 in the DPPH Photocatalytic Stability Test.
  • Example 1 The powder of Example 1 was surface treated with 2% lecithin on powder mass and dispersed in coco-caprylate caprate carrier at 75 weight % zinc oxide using 6% polygly eery 1-2 dipolyhydroxystearate on powder mass as a dispersant.
  • the powder was wetted into dispersion using a propeller blade mixer and transferred to a horizontal media mill for milling.
  • the dispersion was milled using 0.3 mm yttria stabilized zirconia media until the dispersion product produced a DE value of 17.64 in the Dispersion Color Test (milling time was 330 minutes).
  • the resulting product is pourable and has a DE value of 7.04 in the DPPH Photocatalytic Stability Test.
  • Example 1 The powder of Example 1 was surface treated with 2% lecithin on powder mass and dispersed in coco-caprylate caprate carrier at 75 weight % zinc oxide using 6% polyglyceryl-2 dipolyhydroxystearate on powder mass as a dispersant.
  • the powder was wetted into dispersion using a propeller blade mixer and transferred to a horizontal media mill for milling.
  • the dispersion was milled using 0.2 mm yttria stabilized zirconia media until the dispersion product produced a DE value of 19.74 in the Dispersion Color Test (milling time was 450 minutes).
  • the resulting product has a DE value of 6.53 in the DPPH Photocatalytic Stability Test.
  • Example 7 The dispersion of Example 7 was returned to the horizontal media mill for milling. The dispersion was further milled using 0.2 mm yttria stabilized zirconia media until the dispersion product produced a DE value of 25.04 in the Dispersion Color Test (milling time was 870 minutes). The resulting product has a DE value of 4.70 in the DPPH Photocatalytic Stability Test.
  • Example 3 The powder of Example 3 was dispersed in coco-caprylate caprate carrier at 30 weight % zinc oxide using 3% polyglyceryl-2 dipolyhydroxystearate and 1% lecithin on powder mass as dispersants. The dispersion was transferred to a horizontal media mill for milling. The dispersion was milled using 0.3 mm yttria stabilized zirconia media until the dispersion product produced a DE value of 20.51 in the Dispersion Color Test (milling time was 80 minutes). The resulting product has a DE value of 9.65 in the DPPH Photocatalytic Stability Test.
  • Example 9 The dispersion of Example 9 was returned to the horizontal media mill for further milling. The dispersion was milled using 0.3 mm yttria stabilized zirconia media until the dispersion product produced a DE value of 25.45 in the Dispersion Color Test (milling time was 120 minutes). The resulting product has a DE value of 6.92 in the DPPH Photocatalytic Stability Test. Thermogravimetric analysis showed no mass gain features above 400 °C and a small mass loss of 0.36% between 400 °C and 800 °C indicating the product remained as stoichiometric ZnO.
  • Example 2 The powder of Example 2 was subjected to a silanizing surface treatment using 2.5% by weight of octyltriethoxysilane on powder mass.
  • the resultant powder was dispersed in caprylic/capric triglyceride carrier at 70 weight % zinc oxide using 2.5 % by weight polyhydroxystearic acid on powder mass.
  • the powder was wetted into dispersion using a propeller blade mixer. Initially the dispersion displayed a white color.
  • the dispersion was transferred to a horizontal media mill and milled using 0.3 mm yttria stabilized zirconia media until the dispersion product produced a DE value of 17.15 in the Dispersion Color Test (milling time was 120 minutes).
  • the resulting product has a DE value of 9.02 in the DPPH Photocatalytic Stability Test. This DE represents only 49% of the DE value of the starting powder from Example 2.
  • Example 12 [101] The powder of Example 2 was subjected to a surface treatment comprising propylsilsesquioxane/dimethiconol/silicate crosspolymer where the resultant powder is 92% zinc oxide by weight. This powder was dispersed in squalane at 64 weight % zinc oxide using 10 % by weight lecithin on powder mass. Initially the dispersion displayed a white color. The dispersion was transferred to a horizontal media mill and milled using 0.3 mm yttria stabilized zirconia media until the dispersion product produced a DE value of 19.16 in the Dispersion Color Test (milling time was 60 minutes). The resulting product has a DE value of 4.02 in the DPPH Photocatalytic Stability Test.
  • Example 1 The powder of Example 1 was surface treated with silica to yield a powder comprising 92% zinc oxide by weight.
  • the resultant powder was dispersed in caprylic/capric triglyceride carrier at 60.3 weight % zinc oxide using 2% lecithin and 6% polyglyceryl-2 dipolyhydroxystearate on powder mass as dispersants.
  • the powder was wetted into dispersion using a propeller blade mixer and the resultant dispersion displayed an initial tan color. The dispersion was transferred to a horizontal media mill for milling.
  • the dispersion was milled using 0.2 mm yttria stabilized zirconia media until the dispersion product resulted in a DE value of 17.08 in the Dispersion Color Test (milling time was 180 minutes).
  • the resulting product has a DE value of 1.68 in the DPPH Photocatalytic Stability Test.
  • Example 15 Comparative Commercial Zinc Oxides
  • Dispersion Color Test DE values are plotted against the DPPH Photocatalytic Stability DE values for all materials described in Examples 1-15 and presented in FIG. 3. It is apparent from the data that the inventive compositions display distinct characteristics compared to comparative compositions. Note that the data pertaining to the stoichiometric zinc oxides that have been surface treated to even further enhance their inherent photocatalytic stability (Examples 12-14) are denoted in the figure by different symbols than those stoichiometric zinc oxides whose DPPH Photocatalytic Stability DE values reflect the property of the stoichiometric zinc oxide particles without coatings or in which the coating does not significantly affect the photocatalytic stability.
  • Example 17 The powder of Example 1 was surface treated with lecithin at 8% by weight on zinc oxide powder. Lecithin was first dissolved in USP heptane at 40% by weight and the solution was sprayed onto the powder under mixing in an inert environment in an amount sufficient to yield the final target composition. The resultant mixture was dried and heat treated in air at 110 °C. The resulting powder product passes the Hydrophobicity Test. [112] Example 17:
  • Example 1 The powder of Example 1 was surface treated with cetearyl alcohol at 5% by weight on zinc oxide powder. Cetearyl alcohol was first dissolved in USP isopropanol at 20% by weight and the solution was sprayed onto the powder under mixing in an inert environment in an amount sufficient to yield the final target composition. The resultant mixture was dried and heat treated in air at 130 °C to yield an esterified surface treatment. The resulting powder product passes the Hydrophobicity Test.
  • Example 1 The powder of Example 1 was surface treated with octyldodecanol at 8% by weight on zinc oxide powder.
  • Octyldodecanol was first mixed with in USP isopropanol at 40% by weight and the solution was sprayed onto the powder under mixing in an inert environment in an amount sufficient to yield the final target composition.
  • the resultant mixture was dried and heat treated in air at 130 °C to yield an esterified surface treatment.
  • the resulting powder product passes the Hydrophobicity Test.
  • Example 13 The silica surface treated powder of Example 13 was further surface treated with lecithin at 8% by weight on powder. Lecithin was first dissolved in USP heptane at 40% by weight and the solution was sprayed onto the powder under mixing in an inert environment in an amount sufficient to yield the final target composition. The resultant mixture was dried and heat treated in air at 110 °C. The resulting powder product passes the Hydrophobicity Test.
  • Example 13 The silica surface treated powder of Example 13 was further surface treated with cetearyl alcohol at 5% by weight on powder. Cetearyl alcohol was first dissolved in USP isopropanol at 20% by weight and the solution was sprayed onto the powder under mixing in an inert environment in an amount sufficient to yield the final target composition. The resultant mixture was dried and heat treated in air at 130 °C to yield an esterified surface treatment. The resulting powder product passes the Hydrophobicity Test.
  • the silica surface treated powder of Example 13 was further surface treated with octyldodecanol at 8% by weight on powder.
  • Octyldodecanol was first mixed with in USP isopropanol at 40% by weight and the solution was sprayed onto the powder under mixing in an inert environment in an amount sufficient to yield the final target composition.
  • the resultant mixture was dried and heat treated in air at 130 °C to yield an esterified surface treatment.
  • the resulting powder product passes the Hydrophobicity Test.
  • This Example demonstrates a water-in-oil emulsion cosmetic sunscreen preparation.
  • the ingredients in their respective phases are listed below:
  • the formulation is prepared by first combining the ingredients of Phase A in a heated vessel and heated to 80 °C while mixing until uniform. Next, the ingredients of Phase B are combined in a heated vessel and heated to 80 °C while mixing until uniform. Phase A is then added to Phase B while homogenizing using a rotor-stator type homogenizer for 5 minutes at 5000 RPM until uniform. The formula is then cooled to 25 °C while continuously mixed at low speed.
  • the formulation is prepared by first combining the ingredients of Phase A in a heated vessel and heated to 80 °C while mixing until uniform. Next, the ingredients of Phase B are combined in a heated vessel and heated to 80 °C while mixing until uniform. Phase A is then added to Phase B while homogenizing using a rotor-stator type homogenizer for 5 minutes at 5000 RPM until uniform. The formula is then cooled to 25 °C while continuously mixed at low speed.
  • a concealer stick composition providing UV protection is prepared as an anhydrous formula comprising the stoichiometric zinc oxide.
  • the composition is given in the Table below.
  • TABLE 4 Sunscreen Concealer Stick Ingredients
  • Phase A is combined and mixed under high shear conditions.
  • Phase B is added to Phase A and the mixture is heated to 85 °C under high shear conditions.
  • Phase C is dispersed into the mixture under high shear conditions while maintaining the temperature at 85 °C.
  • the batch is then cooled under high shear mixing. Once below 65 °C, Phases D and E are added to the mixture step-wise under high shear mixing conditions. The batch is allowed to continue cooling and dispensed into final packaging once the temperature reaches 60 °C.
  • a concealer stick composition providing UV protection is prepared as an anhydrous formula comprising the stoichiometric zinc oxide.
  • the composition is given in the Table below.
  • Phase A is combined and mixed under high shear conditions.
  • Phase B is added to Phase A and the mixture is heated to 85 °C under high shear conditions.
  • Phase C is dispersed into the mixture under high shear conditions while maintaining the temperature at 85 °C.
  • the batch is then cooled under high shear mixing. Once below 65 °C, Phases D and E are added to the mixture step-wise under high shear mixing conditions. The batch is allowed to continue cooling and dispensed into final packaging once the temperature reaches 60 °C.
  • a cosmetic dry powder sunscreen formulation comprising the stoichiometric zinc oxide.
  • the composition is given in the Table below.
  • a cosmetic dry powder sunscreen formulation comprising the stoichiometric zinc oxide.
  • the composition is given in the Table below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Composite Materials (AREA)
  • Cosmetics (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Optical Filters (AREA)
PCT/US2021/039667 2020-07-02 2021-06-29 Zinc oxide particles, photostable uv filters, and methods of use thereof WO2022006143A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202180055274.9A CN116261553A (zh) 2020-07-02 2021-06-29 氧化锌颗粒、光稳定性uv滤光剂及其使用方法
AU2021299291A AU2021299291A1 (en) 2020-07-02 2021-06-29 Zinc oxide particles, photostable UV filters, and methods of use thereof
KR1020217042724A KR102391600B1 (ko) 2020-07-02 2021-06-29 산화아연 입자, 광안정성 uv 필터 및 이의 사용 방법
KR1020227013753A KR20230020936A (ko) 2020-07-02 2021-06-29 산화아연 입자, 광안정성 uv 필터 및 이의 사용 방법
MX2023000248A MX2023000248A (es) 2020-07-02 2021-06-29 Particulas de oxido de zinc, filtros uv fotoestables, y metodos de uso de los mismos.
IL299410A IL299410A (en) 2020-07-02 2021-06-29 Zinc oxide particles, light-resistant UV filters and methods of using them
CA3184737A CA3184737A1 (en) 2020-07-02 2021-06-29 Zinc oxide particles, photostable uv filters, and methods of use thereof
JP2022581353A JP2023532922A (ja) 2020-07-02 2021-06-29 酸化亜鉛粒子、光安定性ｕｖフィルター及びその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063047856P 2020-07-02 2020-07-02
US63/047,856 2020-07-02
US17/186,518 2021-02-26
US17/186,518 US11672744B2 (en) 2020-07-02 2021-02-26 Zinc oxide particles, photostable UV filters, and methods of use thereof

Publications (1)

Publication Number Publication Date
WO2022006143A1 true WO2022006143A1 (en) 2022-01-06

Family

ID=76764977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/039667 WO2022006143A1 (en) 2020-07-02 2021-06-29 Zinc oxide particles, photostable uv filters, and methods of use thereof

Country Status (10)

Country Link
US (2) US11672744B2 (ko)
EP (1) EP3943450A1 (ko)
JP (1) JP2023532922A (ko)
KR (2) KR102391600B1 (ko)
CN (1) CN116261553A (ko)
AU (1) AU2021299291A1 (ko)
CA (1) CA3184737A1 (ko)
IL (1) IL299410A (ko)
MX (1) MX2023000248A (ko)
WO (1) WO2022006143A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672744B2 (en) 2020-07-02 2023-06-13 Nanophase Technologies Corporation Zinc oxide particles, photostable UV filters, and methods of use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240040954A (ko) 2022-09-22 2024-03-29 주식회사 로터스켐랩 2차원 다공성 산화아연 구조체 및 그 제조 방법
CN116983231A (zh) * 2023-08-21 2023-11-03 广州君奕科技有限公司 一种生物型防晒、修护屏障添加剂组合物、制备方法、应用和防晒数值的测试方法
CN118085798A (zh) * 2024-03-20 2024-05-28 东莞市高图新材料有限公司 一种用于新能源电池的uv绝缘保护胶及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140141968A1 (en) * 2012-11-02 2014-05-22 Industrial Technology Research Institute Photocatalyst material and method for fabricating the same
US9139737B1 (en) * 2011-11-21 2015-09-22 Nanophase Technologies Corporation Multifunctional coated powders and high solids dispersions
US10590278B2 (en) * 2017-04-10 2020-03-17 Nanophase Technologies Corporation Coated powders having high photostability

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR35660E (fr) 1928-04-07 1930-03-27 Dispositif de filtrage de courants électriques notamment pour appareils de radiosignalisation
FR38975E (fr) 1929-12-04 1931-08-10 Groupes gyroscopiques de stabilisation et de direction
US2616842A (en) 1951-01-13 1952-11-04 Sheer Charles Arc process for the production of fume
US2657149A (en) 1952-10-21 1953-10-27 Du Pont Method of esterifying the surface of a silica substrate having a reactive silanol surface and product thereof
BE556585A (ko) 1956-04-11
US2885366A (en) 1956-06-28 1959-05-05 Du Pont Product comprising a skin of dense, hydrated amorphous silica bound upon a core of another solid material and process of making same
US3437502A (en) 1968-03-28 1969-04-08 Du Pont Titanium dioxide pigment coated with silica and alumina
US3920865A (en) 1969-03-29 1975-11-18 Degussa Process of hydrophorizing highly dispersed metal or metalloid oxides
US3900762A (en) 1971-07-06 1975-08-19 Sheer Korman Associates Method and apparatus for projecting materials into an arc discharge
US3849152A (en) 1972-11-06 1974-11-19 Ferro Corp Polysiloxane encapsulation of pigments
US4056494A (en) 1975-03-07 1977-11-01 American Lecithin Company Joint suspensions of mixed pigmentations achieved by active effects of plant phosphatides
US4305853A (en) 1980-03-11 1981-12-15 American Lecithin Company Chemical modification of metal oxides and lecithin materials
US4454288A (en) 1982-12-02 1984-06-12 Dow Corning Corporation Surface treatment of inorganic fillers
JPS59227765A (ja) 1983-06-04 1984-12-21 科学技術庁金属材料技術研究所長 セラミツクスの超微粒子の製造法
US4845054A (en) 1985-06-14 1989-07-04 Focus Semiconductor Systems, Inc. Low temperature chemical vapor deposition of silicon dioxide films
US4732369A (en) 1985-10-30 1988-03-22 Hitachi, Ltd. Arc apparatus for producing ultrafine particles
US5223250A (en) 1991-02-05 1993-06-29 Sun Smart, Inc. Visibly transparent UV sunblock cosmetic compositions
US5441726A (en) 1993-04-28 1995-08-15 Sunsmart, Inc. Topical ultra-violet radiation protectants
US5460701A (en) 1993-07-27 1995-10-24 Nanophase Technologies Corporation Method of making nanostructured materials
US5486831A (en) 1994-04-21 1996-01-23 Rowland; Landon L. Multi-mode missile seeker with adjunct sensor blocking an electronically scanned radio frequency aperture using an off-boresight direction finding process
US5756788A (en) 1995-06-14 1998-05-26 Sunsmart, Inc. Silicone polymer-coated, hydrophobized metal oxides
US5565591A (en) 1995-06-14 1996-10-15 Sunsmart Silicone polymers for the modification of titanium dioxide
US5486631A (en) 1995-06-14 1996-01-23 Siltech Inc. Silicone polymers for the modification of zinc oxide
US5536492A (en) 1995-06-14 1996-07-16 Siltech Inc. Cosmetic compositions containing hydrophobized zinc oxide
US5653794A (en) 1995-12-01 1997-08-05 Scm Chemicals, Inc. Silane treated inorganic pigments
EP0891387B1 (en) 1996-04-04 2004-05-26 Nanophase Technologies Corporation Siloxane star-graft polymers, ceramic powders coated therewith and method of preparing coated ceramic powders
US5993967A (en) 1997-03-28 1999-11-30 Nanophase Technologies Corporation Siloxane star-graft polymers, ceramic powders coated therewith and method of preparing coated ceramic powders
GB9811377D0 (en) 1998-05-27 1998-07-22 Isis Innovations Ltd Compositions
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
US6669823B1 (en) 2002-06-17 2003-12-30 Nanophase Technologies Corporation Process for preparing nanostructured materials of controlled surface chemistry
EP1618575B1 (en) * 2003-04-28 2019-10-23 Showa Denko K.K. Valve acting metal sintered body, production method therefor and solid electrolytic capacitor
JP4100341B2 (ja) 2003-12-26 2008-06-11 新神戸電機株式会社 リチウム二次電池用正極材料及びそれを用いたリチウム二次電池
IL206909A0 (en) 2008-01-11 2010-12-30 Antaria Ltd Mesoporous zinc oxide powder and method for production thereof
JP4655105B2 (ja) 2008-04-30 2011-03-23 住友金属鉱山株式会社 紫外線遮蔽透明樹脂成形体およびその製造方法
CN103459318B (zh) 2011-04-28 2015-10-14 堺化学工业株式会社 六方柱状氧化锌颗粒、其制造方法、以及混配有该颗粒的化妆料、散热性填料、散热性树脂组合物、散热性脂膏和散热性涂料组合物
US10555892B1 (en) 2017-03-09 2020-02-11 Nanophase Technologies Corporation Functionalized siloxane or polysiloxane coated particles with enhanced light filtering properties
US11672744B2 (en) * 2020-07-02 2023-06-13 Nanophase Technologies Corporation Zinc oxide particles, photostable UV filters, and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139737B1 (en) * 2011-11-21 2015-09-22 Nanophase Technologies Corporation Multifunctional coated powders and high solids dispersions
US20140141968A1 (en) * 2012-11-02 2014-05-22 Industrial Technology Research Institute Photocatalyst material and method for fabricating the same
US10590278B2 (en) * 2017-04-10 2020-03-17 Nanophase Technologies Corporation Coated powders having high photostability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN DAIMEI, WANG ZHIHONG, REN TIEZHEN, DING HAO, YAO WENQING, ZONG RUILONG, ZHU YONGFA: "Influence of Defects on the Photocatalytic Activity of ZnO", THE JOURNAL OF PHYSICAL CHEMISTRY C, AMERICAN CHEMICAL SOCIETY, US, vol. 118, no. 28, 17 July 2014 (2014-07-17), US , pages 15300 - 15307, XP055883647, ISSN: 1932-7447, DOI: 10.1021/jp5033349 *
WANG JING; CHEN RUOSONG; XIANG LAN; KOMARNENI SRIDHAR: "Synthesis, properties and applications of ZnO nanomaterials with oxygen vacancies: A review", CERAMICS INTERNATIONAL, ELSEVIER, AMSTERDAM., NL, vol. 44, no. 7, 3 February 2018 (2018-02-03), NL , pages 7357 - 7377, XP085357742, ISSN: 0272-8842, DOI: 10.1016/j.ceramint.2018.02.013 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672744B2 (en) 2020-07-02 2023-06-13 Nanophase Technologies Corporation Zinc oxide particles, photostable UV filters, and methods of use thereof
US12083200B2 (en) 2020-07-02 2024-09-10 Nanophase Technologies Corporation Zinc oxide particles, photostable UV filters, and methods of use thereof

Also Published As

Publication number Publication date
US12083200B2 (en) 2024-09-10
IL299410A (en) 2023-02-01
CN116261553A (zh) 2023-06-13
KR20220004772A (ko) 2022-01-11
MX2023000248A (es) 2023-02-09
JP2023532922A (ja) 2023-08-01
CA3184737A1 (en) 2022-01-06
US20230363990A1 (en) 2023-11-16
US11672744B2 (en) 2023-06-13
US20220000731A1 (en) 2022-01-06
KR102391600B1 (ko) 2022-04-28
EP3943450A1 (en) 2022-01-26
KR20230020936A (ko) 2023-02-13
AU2021299291A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US11672744B2 (en) Zinc oxide particles, photostable UV filters, and methods of use thereof
US11499054B2 (en) Coated powders having high photostability
Niculae et al. Rice bran and raspberry seed oil-based nanocarriers with self-antioxidative properties as safe photoprotective formulations
AU2008338479A1 (en) Enhanced photostability of avobenzone in the presence of zinc oxide using phosphate-based emulsifiers
CN113332169B (zh) 一种个人护理防晒组合物、制备方法及应用
EP2982363A1 (en) Two component system for cosmetic formulations
EP4027967B1 (en) Lipophillically dispersed phenolic polymer particles
US20220016003A1 (en) Particulates of polyphenolics and dispersions thereof
WO2022016117A1 (en) Particulates of polyphenolics and dispersions thereof
US20240293313A1 (en) Method of enhancing the efficacy and stability of ingredients in suspensions
KR101238379B1 (ko) 자외선흡수제가 포집된 이산화티타늄 캡슐 및 이를 함유하는 화장료 조성물
Hewitt New and emerging sunscreen technologies

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 20217042724

Country of ref document: KR

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21833181

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022581353

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3184737

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021299291

Country of ref document: AU

Date of ref document: 20210629

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21833181

Country of ref document: EP

Kind code of ref document: A1